ClinicalTrials.gg
CompletedNCT01398111TRIPLE 1Updated Oct 29, 2021

Pharmacokinetic Interaction Study of Glycopyrrolate and Formoterol in Healthy Volunteers

A Phase 1 interventional study of Glycopyrrolate + Formoterol and Glycopyrrolate in COPD, sponsored by Chiesi Farmaceutici S.p.A.. Completed at 1 site in Belgium. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-10-29.

Sponsored by Chiesi Farmaceutici S.p.A. · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive — 2 open to participants now, 2 under way, 1 of them phase 3. Glycopyrrolate · Pulmonary Disease, Chronic Obstructive.

Enrollment
54th of 73
44 · median 152
Started
2011
with 3 others
Phase 1
7 of 73
none open now
Registered
18th of 73
by date
Lead sponsor
13 of 73
Chiesi Farmaceutici S.p.A.

Among the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, this one is the 54th largest by enrollment, is one of 4 that started in 2011, is one of 7 in phase 1, and was the 18th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

2 of the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About glycopyrrolate

Glycopyrrolate: first FDA approval 1961 (ROBINUL FORTE), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

This study will be carried out in healthy volunteers with the primary objective to evaluate the pharmacokinetic interaction between Glyco and Formoterol administered using a pressurised metered dose inhaler (pMDI).

03

Conditions studied

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  • Males and females healthy volunteers aged 18-65 years will be included in the study.
05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
44 participants (actual)

Study arms

  • Active comparator
    Treatment R2

    Drug: Formoterol

  • Active comparator
    Treatment R1

    Drug: Glycopyrrolate

  • Placebo comparator
    Placebo

    Drug: Placebo

  • Experimental
    Treatment T

    Drug: Glycopyrrolate + Formoterol

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics: formoterol and glyco AUC0-t

    Area under the plasma concentration curve observed from administration up to the last measurable concentration.

    Time frame: from pre-dose to 32 hours after administration

  2. Pharmacokinetics: formoterol and glyco Cmax

    Maximum plasma concentration

    Time frame: from pre-dose to 32 hours after administration

Secondary outcomes

  1. Additional pharmacokinetic variables

    Plasma Glyco AUC0-30min, AUC0-32h, AUC0-inf, tmax and t1/2 - Plasma Formoterol AUC0-30min, AUC0-24h, AUC0-inf, tmax and t1/2.

    Time frame: from pre-dose to 32 hours post dose

  2. Serum potassium

    Serum potassium Cmin, tmin and AUC0-24h

    Time frame: From pre-dose to 24 hours after administration

  3. Plasma glucose

    Plasma glucose Cmax, tmax and AUC0-24h

    Time frame: from pre-dose to 24 hours after administration

  4. Lung function

    FEV1 in order to assess potential occurrence of paradoxical bronchospasm

    Time frame: from pre-dose to 1 hour after administration

  5. Vital signs

    heart rate (HR), systolic blood pressure (SBP), diastolic blood pressure (DBP).

    Time frame: from pre-dose to 24 hours after administration

  6. ECG

    12-lead ECG parameters: HR, RR, PR, QRS, QT, QTcB, QTcF

    Time frame: from pre-dose to 24 hours after administration

07

Study locations

1 site
  • Clinical Pharmacology Unit - SGS Life Science Services
    Antwerpen, Lange Beeldekensstraat 267 2060, Belgium
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2011, a primary completion of Aug 2011 and a completion of Aug 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2011
First posted
Jul 20, 2011
Start
May 2011
Primary completionActual
Aug 2011
CompletionActual
Aug 2011
Last update
Oct 29, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 29, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01398111
Responsible party
Sponsor
First posted
Jul 20, 2011
Start date
May 2011
Primary completion
Aug 2011
Completion
Aug 2011
Last update
Oct 29, 2021

Study contacts

Lien Gheyle, MD
principal investigator · Clinical Pharmacology Unit at SGS Life Sciences - Antwerpen (Belgium)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Glycopyrrolate · Formoterol

Start the discussion